Nathaniel R Landau
Overview
Explore the profile of Nathaniel R Landau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
5380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tada T, Norton T, Leibowitz R, Landau N
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38658032
Background: While immunotherapy has been highly successful for the treatment of some cancers, for others, the immune response to tumor antigens is weak leading to treatment failure. The resistance of...
2.
Valeri E, Unali G, Piras F, Abou-Alezz M, Pais G, Benedicenti F, et al.
Mol Ther
. 2023 Nov;
32(1):124-139.
PMID: 37990494
Quiescent human hematopoietic stem cells (HSC) are ideal targets for gene therapy applications due to their preserved stemness and repopulation capacities; however, they have not been exploited extensively because of...
3.
Tada T, Minnee J, Landau N
Proc Natl Acad Sci U S A
. 2023 May;
120(23):e2303509120.
PMID: 37252952
Vectored immunoprophylaxis was first developed as a means of establishing engineered immunity to HIV using an adenoassociated viral vector expressing a broadly neutralizing antibody. We applied this concept to establish...
4.
Tada T, Peng J, Dcosta B, Landau N
JCI Insight
. 2023 Apr;
8(7).
PMID: 37036004
Currently authorized COVID-19 vaccines induce humoral and cellular responses to epitopes in the SARS-CoV-2 spike protein, though the relative roles of antibodies and T cells in protection are not well...
5.
Duerr R, Zhou H, Tada T, Dimartino D, Marier C, Zappile P, et al.
iScience
. 2023 Feb;
26(2):106075.
PMID: 36844451
The emergence of recombinant viruses is a threat to public health, as recombination may integrate variant-specific features that together result in escape from treatment or immunity. The selective advantages of...
6.
Tada T, Dcosta B, Zhou H, Landau N
iScience
. 2023 Feb;
26(2):106092.
PMID: 36741912
The emergence of SARS-CoV-2 variants with highly mutated spike proteins has presented an obstacle to the use of monoclonal antibodies for the prevention and treatment of SARS-CoV-2 infection. We show...
7.
Tada T, Dcosta B, Minnee J, Landau N
bioRxiv
. 2023 Jan;
PMID: 36711584
Vectored immunoprophylaxis was first developed as a means to establish engineered immunity to HIV through the use of an adeno-associated viral vector expressing a broadly neutralizing antibody. We have applied...
8.
Tada T, Dcosta B, Zhou H, Landau N
bioRxiv
. 2023 Jan;
PMID: 36656772
The emergence of SARS-CoV-2 variants with highly mutated spike proteins has presented an obstacle to the use of monoclonal antibodies for the prevention and treatment of SARS-CoV-2 infection. We show...
9.
Christie S, Tada T, Yin Y, Bhardwaj A, Landau N, Rothenberg E
Sci Adv
. 2022 Dec;
8(49):eabo3977.
PMID: 36490345
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a global health crisis after its emergence in 2019. Replication of the virus is initiated by binding of the viral spike (S)...
10.
Britton D, Punia K, Mahmoudinobar F, Tada T, Jiang X, Renfrew P, et al.
Biochem Eng J
. 2022 Aug;
187:108596.
PMID: 36034180
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic since December 2019, and with it, a push for innovations in rapid testing and neutralizing antibody treatments in...